MedPath

RETEVMO

RETEVMO

Approved
DIN Number

02516926

Drug Class

Human

Market Date

Jan 21, 2022

Company
HC

loxo oncology inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02516926
AIG Number0162988002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
L01EX22 SELPERCATINIB
Product Specifications
Dosage FormCapsule
Route of AdministrationOral
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

SELPERCATINIBActive
Strength: 80 MG
Monograph: SELPERCATINIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.